Biotech IV Monitor

IDYA — IDEAYA Biosciences Inc.

$3.1B market cap · 6 upcoming readouts tracked

Clinical trial readout dates for IDEAYA Biosciences Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.

Next readoutJanuary 2027in ~2 months
Upcoming readouts63 Phase 3
Market cap$3.1B
Cash & investments$1.25B~10 quarters at last loss rate
Recent 8-K filings1latest 2026-11-03

Upcoming readouts

Phase 2/3 IDE196
Metastatic Uveal Melanoma · NCT05987332
January 2027
Ongoing
Phase 1/2 IDE196
Metastatic Uveal Melanoma; Cutaneous Melanoma · NCT03947385
January 2027
Recruiting
Phase 2 Darovasertib
Uveal Melanoma · NCT05907954
April 2027
Ongoing
Phase 1/2 IDE849
Small-cell Lung Cancer; Neuroendocrine Carcinomas · NCT07174583
July 2029
Recruiting
Phase 3 Darovasertib
Uveal Melanoma · NCT07015190
October 2030
Recruiting
Phase 3 Darovasertib
Uveal Melanoma · NCT07804186
March 2034
Recruiting

Cash position

IDEAYA Biosciences Inc. reported $1.25B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $126M; at that rate the cash would last about 10 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-03

Companies working on similar indications

Discussion

No messages yet. If you follow IDYA, you can start the conversation.
Track IDYA in real time
See live implied volatility for IDYA and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on IDYA
Contact — questions or corrections about IDYA: dukeupt@gmail.com